Experimental drug aims to tame stubborn autoimmune diseases
NCT ID NCT07655453
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests an experimental drug called STR-P005 in people with autoimmune diseases that have come back or not improved with standard treatments. The drug is given through an IV in multiple doses. The main goal is to check safety and see how the body handles the drug. Up to 36 adults aged 18 to 75 with certain blood cell markers can join.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
STR-P005
What this could lead to
If successful, this could point toward a new treatment option for people with autoimmune diseases that have not responded to standard therapies.
What could go wrong
This is a very early, small study (36 people) focused mainly on safety. The drug may not work as hoped, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.